StreetInsider.com News Articles

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

XChange TEC signs non-binding letter to acquire AI firm First Cycle

Thu, 13 Aug 2026 08:00:53 -0400

XChange TEC.INC (Nasdaq: XHG), an insurance agency and technology platform operating in China and Hong Kong, has signed a non-binding letter of intent to acquire First Cycle, INC., an artificial intelligence technology company headquartered in Hong Kong, according to a press release dated Aug. 13, 2026.

First Cycle develops AI-driven solutions using machine learning, natural language processing, and agentic AI technologies aimed at reducing manual workloads in insurance workflows, including underwriting and claims processing. The company's AI agents operate across digital, voice, and mobile channels to capture, validate, and route claims in real time.

XChange said the proposed acquisition is intended to

XChange TEC signs non-binding letter to acquire AI firm First Cycle

Thu, 13 Aug 2026 08:00:53 -0400

XChange TEC.INC (Nasdaq: XHG), an insurance agency and technology platform operating in China and Hong Kong, has signed a non-binding letter of intent to acquire First Cycle, INC., an artificial intelligence technology company headquartered in Hong Kong, according to a press release dated Aug. 13, 2026.

First Cycle develops AI-driven solutions using machine learning, natural language processing, and agentic AI technologies aimed at reducing manual workloads in insurance workflows, including underwriting and claims processing. The company's AI agents operate across digital, voice, and mobile channels to capture, validate, and route claims in real time.

XChange said the proposed acquisition is intended to

XChange TEC.INC Announces Intent to Acquire First Cycle, INC., Accelerating AI-Powered Insurance Transformation

Thu, 13 Aug 2026 08:00:00 -0400

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- XChange TEC.INC (Nasdaq: XHG) ("XChange" or the "Company"), an insurance agency and insurance technology platform serving consumers across the People's Republic of China and Hong Kong, today announced that it has signed a non-binding letter of intent to acquire First Cycle, INC. ("First Cycle"), a growing artificial intelligence ("AI") technology company headquartered in Hong Kong. The proposed acquisition represents a pivotal step in XChange's strategic vision to become an AI-driven insurance ecosystem platform in the

XChange TEC.INC Announces Intent to Acquire First Cycle, INC., Accelerating AI-Powered Insurance Transformation

Thu, 13 Aug 2026 08:00:00 -0400

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- XChange TEC.INC (Nasdaq: XHG) ("XChange" or the "Company"), an insurance agency and insurance technology platform serving consumers across the People's Republic of China and Hong Kong, today announced that it has signed a non-binding letter of intent to acquire First Cycle, INC. ("First Cycle"), a growing artificial intelligence ("AI") technology company headquartered in Hong Kong. The proposed acquisition represents a pivotal step in XChange's strategic vision to become an AI-driven insurance ecosystem platform in the

XChange TEC.INC Announces Intent to Acquire First Cycle, INC., Accelerating AI-Powered Insurance Transformation

Thu, 13 Aug 2026 08:00:00 -0400

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- XChange TEC.INC (Nasdaq: XHG) ("XChange" or the "Company"), an insurance agency and insurance technology platform serving consumers across the People's Republic of China and Hong Kong, today announced that it has signed a non-binding letter of intent to acquire First Cycle, INC. ("First Cycle"), a growing artificial intelligence ("AI") technology company headquartered in Hong Kong. The proposed acquisition represents a pivotal step in XChange's strategic vision to become an AI-driven insurance ecosystem platform in the

XChange TEC.INC Announces Intent to Acquire First Cycle, INC., Accelerating AI-Powered Insurance Transformation

Thu, 13 Aug 2026 08:00:00 -0400

SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- XChange TEC.INC (Nasdaq: XHG) ("XChange" or the "Company"), an insurance agency and insurance technology platform serving consumers across the People's Republic of China and Hong Kong, today announced that it has signed a non-binding letter of intent to acquire First Cycle, INC. ("First Cycle"), a growing artificial intelligence ("AI") technology company headquartered in Hong Kong. The proposed acquisition represents a pivotal step in XChange's strategic vision to become an AI-driven insurance ecosystem platform in the

Form 6-K XChange TEC.INC For: Mar 31

Thu, 16 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260716/26780075.html

Form 6-K XChange TEC.INC For: Mar 31

Thu, 16 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260716/26780075.html

Form F-6EF XChange TEC.INC/ADR Filed by: BANK OF NEW YORK / ADR DIVISION

Tue, 19 May 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260519/26521418.html

Form F-6EF XChange TEC.INC/ADR Filed by: BANK OF NEW YORK / ADR DIVISION

Tue, 19 May 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260519/26521418.html

Form 6-K XChange TEC.INC For: Apr 17

Fri, 17 Apr 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260417/26331067.html

Form 6-K XChange TEC.INC For: Apr 17

Fri, 17 Apr 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260417/26331067.html

Form 424B5 XChange TEC.INC

Thu, 16 Apr 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260416/26325585.html

Form 424B5 XChange TEC.INC

Thu, 16 Apr 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260416/26325585.html

Form 6-K XChange TEC.INC For: Apr 07

Tue, 07 Apr 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260407/26283824.html

Form 6-K XChange TEC.INC For: Apr 07

Tue, 07 Apr 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260407/26283824.html

Form EFFECT XChange TEC.INC

Thu, 02 Apr 2026 06:07:00 -0400
si-local-file:///var/storage/secattach/20260402/26262028.html